Menu
Menu
The Oncology Institute of Hope and Innovation is a leader in clinical studies, with the goal to advance the treatment of cancer. We conduct more trials than most other community cancer groups in the US. Our research helps us evaluate the effectiveness of treatment, reduce the risk of complications, lower costs and save resources, and continually refine our clinical approach to cancer care.
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared with Eculizumab in Adult Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First-Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase III Double-Blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290)
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase III Double-Blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Single-Arm, Roll-Over Study to Provide Continued Treatment with Darolutamide in Participants Who Were Enrolled in Previous Bayer-Sponsored Studies
3300 E. South St.
Suite 304
Long Beach, CA 90805
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Collection and Distribution of Biofluids and Tumor Tissue Biospecimens for Research Purposes
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Randomized, Non-Comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer delete ? 2 cm with Safety Run-In, Assessing Nivolumab + Palbociclib + Anastrozole (CheckMate 7A8: CHECKpoint Pathway and NivoluMAb Clinical Trial Evaluation 7A8)
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab Versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients with High-Risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAÏVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
21605 Hawthorne Blvd.
Suite 200
Torrance, CA 90503
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (DS-8201A), an Anti-HER2-Antibody Drug Conjugate, Versus Treatment of Investigator’s Choice for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated with T-DM1
3300 E. South St.
Suite 304
Long Beach, CA 90805
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A long-term study to further evaluate the risk of hepatotoxicity associated with TURALIO™ (pexidartinib) treatment.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Parallel-Group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) with MabThera® in Subjects with Previously Untreated, Stage II-IV, Cluster of Differentiation (CD)20-Positive, Low Tumour Burden Follicular Lymphoma
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)
1513 S. Grand Ave.
Suite 300
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo In Combination with Lenalidomide plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1513 S. Grand Ave.
Suite 300
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer
900 S. Main St.
Suite 204
Corona, CA 92882
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
900 S. Main St.
Suite 204
Corona, CA 92882
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Phase 3 Study of Platinum-Based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who Progressed on or after Treatment with Platinum Based Chemotherapy
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), PostPolycythemia Vera MF (Post-PV-MF), Or PostEssential Thrombocythemia MF (PostET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor Intolerant Myelofibrosis
900 S. Main St.
Suite 204
Corona, CA 92882
1513 S. Grand Ave.
Suite 300
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Phase 3 Trial Of Maintenance With Selinexor/ Placebo After Combination Chemotherapy For Patients With Advanced Or Recurrent Endometrial Cancer.
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Open-Label, Multicenter, Phase IB Dose-Escalation Study of MEN1611, a PI3K Inhibitor Combined with Trastuzumab ± Fulvestrant, in Subjects with PIK3CA Mutated HER2-Positive Locally Recurrent Unresectable (Advanced) or Metastatic (A/M) Breast Cancer Progressed To Anti-HER2 Based Therapy
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Open-Label, Multicenter, Phase IB/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients with PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU, and Anti-EGFR Containing Regimens
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
18433 Roscoe Blvd.
Suite 106
Northridge, CA 91325
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
425 Haaland Dr.
Ste. 103
Thousand Oaks, CA 91361
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
50 Bellefontaine St.
Suite 401
Pasadena, CA 91105
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2a Open-Label Study to Investigate Safety and Tolerability (Including the Maximum Tolerated Dose), Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura.
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase II/III, Randomized, Multicenter Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
21605 Hawthorne Blvd.
Suite 200
Torrance, CA 90503
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
LUNAR: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) Concurrent with Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (NSCLC) Following Platinum Failure
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase III Open-Label, Multicenter, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Two-Period, Cross-Over, Phase 2 Study, Comparing the Pharmacokinetics and Assessing Safety and Tolerability of Peripheral and Central Intravenous Administration of Melflufen in Patients with Relapsed and Refractory Multiple Myeloma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
1513 S. Grand Ave.
Suite 300
Los Angeles, CA 90015
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
4500 Brockton Ave.
Suite 316
Riverside, CA 92506
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1b/2 Open-Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1513 S. Grand Ave.
Suite 300
Los Angeles, CA 90015
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial
3300 E. South St.
Suite 304
Long Beach, CA 90805
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated with Complement Inhibitors
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not Previously Treated with Complement Inhibitors
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Open-Label, Single-Arm Trial To Evaluate Antitumor Activity, Safety, And Pharmacokinetics Of SAR408701 Used In Combination With Ramucirumab In Metastatic, Non-Squamous, Non–Small-Cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-Positive Tumors, Previously Treated With Platinum-Based Chemotherapy And An Immune Checkpoint Inhibitor.
1513 S. Grand Ave.
Suite 300
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Disease Registry Encompassing the Care of Patients with Multiple Myeloma on Panobinostat (RECOMM)
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated with JAK Inhibitor Therapy
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-label, Nonrandomized, Phase 1 Drug-Drug Interaction Study to Evaluate the Pharmacokinetics of Belinostat in Combination with Atazanavir in Patients with Advanced Relapsed/Refractory Solid Tumors or Hematological Malignancies
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
21605 Hawthorne Blvd.
Suite 200
Torrance, CA 90503
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER)
3300 E. South St.
Suite 304
Long Beach, CA 90805
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination with an Anti-PD-1 in Patients with Advanced Solid Tumors
3300 E. South St.
Suite 304
Long Beach, CA 90805
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
The MT Group MTG-022: Discovery and Evaluation of Biomarkers/ Pharmacogenomics for the Diagnosis and Personalized Management of Patients
900 S. Main St.
Suite 204
Corona, CA 92882
1513 S. Grand Ave.
Suite 300
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkins Lymphoma
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
21605 Hawthorne Blvd.
Suite 200
Torrance, CA 90503
1135 S. Sunset Ave.
Suite 301
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety between TRS003 and China-approved Bevacizumab Administered in Combination with Paclitaxel-Carboplatin in Subjects with Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC)
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2b, Open-Label, Single-Arm Study of ZW25 Monotherapy in Subjects with Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
3300 E. South St.
Suite 304
Long Beach, CA 90805
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
© 2021 The Oncology Institute of Hope and Innovation. All rights reserved.
English
Chinese (Simplified)
Korean
Spanish
Vietnamese